WO2004005462A2 - Reactifs et methodes d'identification et de modulation de l'expression de genes de senescence des tumeurs - Google Patents

Reactifs et methodes d'identification et de modulation de l'expression de genes de senescence des tumeurs Download PDF

Info

Publication number
WO2004005462A2
WO2004005462A2 PCT/US2003/020425 US0320425W WO2004005462A2 WO 2004005462 A2 WO2004005462 A2 WO 2004005462A2 US 0320425 W US0320425 W US 0320425W WO 2004005462 A2 WO2004005462 A2 WO 2004005462A2
Authority
WO
WIPO (PCT)
Prior art keywords
expression
compound
cell
cellular gene
gene
Prior art date
Application number
PCT/US2003/020425
Other languages
English (en)
Other versions
WO2004005462A3 (fr
Inventor
Igor B. Roninson
Bey-Dih Chang
Original Assignee
The Board Of Trustees Of The University Of Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The University Of Illinois filed Critical The Board Of Trustees Of The University Of Illinois
Priority to MXPA05000159A priority Critical patent/MXPA05000159A/es
Priority to CA002491143A priority patent/CA2491143A1/fr
Priority to JP2004519674A priority patent/JP2006500920A/ja
Priority to EP03739349A priority patent/EP1572932A4/fr
Priority to US10/520,142 priority patent/US20070128596A1/en
Priority to AU2003245743A priority patent/AU2003245743A1/en
Publication of WO2004005462A2 publication Critical patent/WO2004005462A2/fr
Publication of WO2004005462A3 publication Critical patent/WO2004005462A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Definitions

  • This invention is related to changes in cellular gene expression and compounds that produce changes in cellular gene expression.
  • the invention is related to the identification of genes the expression of which is associated with the development of senescence in mammalian tumor cells upon treatment with cytotoxic agents, including chemo therapeutic drugs, such as doxorubicin, and ionizing radiation. More specifically, the invention provides methods for identifying compounds that modulate expression of these cellular genes.
  • the invention also provides reagents that are recombinant mammalian cells containing recombinant expression constructs that express a reporter gene under the transcriptional control of a promoter for a senescence-associated gene expression, and methods for using such cells for identifying compounds that modulate expression of these cellular genes and produce senescence in said cells.
  • Compounds identified using the methods of the invention are provided for use in therapeutic methods for treating diseases and disorders relating to abnormal cellular proliferation or neoplastic cell growth. Diagnostic methods, particularly methods for monitoring the efficacy of anticancer treatment regimes, are also provided by this invention.
  • Cancer remains one of the leading causes of death in the United States.
  • Current treatment for cancer includes chemotherapy and radiation, but these treatments are not invariably cytotoxic to all tumor cells. Some of the cells that survive treatment recover and resume proliferation, while others undergo permanent growth arrest. Irreversible proliferation arrest in tumor cells treated with anticancer agents may result from cell death or permanent growth arrest. Although the mechanism of damage-induced cell death is a subject of active investigation, little is known about the determinants of terminal growth arrest in tumor cells.
  • Induction of the senescent phenotype in treated tumor cells has been observed in cells treated with a variety of cytotoxic agents, such as doxorubicin, aphidicolin, cisplatin, ionizing radiation, cytarabine, etoposide or taxol; this response is detectable in treated tumor cells even at the lowest concentration of a cytotoxic agent that produces detectable growth inhibition (Chang et al, 1999a, ibid.). Senescence of tumor cells can be produced upon treatment not only with cytotoxic agents but also with vitamin A derivatives, retinoids, under conditions that produce growth inhibition with only minimal cytotoxicity (Chang et al, 1999a, ibid.).
  • cytotoxic agents such as doxorubicin, aphidicolin, cisplatin, ionizing radiation, cytarabine, etoposide or taxol
  • Senescence of tumor cells can be produced upon treatment not only with cytotoxic agents but also with vitamin A derivatives,
  • Retinoid-induced senescence in breast carcinoma cells is associated with co-induction of several growth-inhibitory genes, as described in Dokmanovic et al. (2002, Cancer Biol Ther. 1_: 16-19) and in co-owned and co-pending U.S. Serial No. 09/865,879, filed May 25, 2001, incorporated by reference herein.
  • Tumor cells can also be induced to undergo senescence through ectopic expression of tumor suppressors (Sugrue et al, 1997, Proc. Natl Acad. Sci.
  • This invention provides genes that are induced or repressed in senescent cells and arise upon treatment with cytotoxic agents, as well as reagents and methods for identifying compounds that induce or repress such genes.
  • the invention also advantageously provides compounds that mimic the effects of cytotoxic agents in inhibiting the growth of tumor cells without producing toxicity associated with these agents. Most preferably the mimicked effect is induction of senescence in mammalian tumor cells.
  • the invention provides a method for identifying a compound that induces senescence in a mammalian cell.
  • the method comprises the steps of culturing the mammalian cell in the presence and absence of the compound; assaying expression of at least one cellular gene set forth in Table 2A in said cell in the presence of the compound with expression of said gene in the cell in the absence of the compound; and identifying compounds that induce senescence when expression of at least one cellular gene in Table 2A is higher in the presence of the compound than in the absence of the compound.
  • the mammalian cell is a p53 deficient cell.
  • the mammalian cell is a tumor cell.
  • the cellular gene is a human gene, most preferably BTG1, BTG2, EPLIN, WLPl, Maspin, MIC-1, IGFBP-6 or amphiregulin.
  • Expression of cellular genes according to the method is preferably detected by hybridization to a complementary nucleic acid, by using an immunological reagent or by assaying for an activity of the cellular gene product.
  • the mammalian cell is a recombinant mammalian cell comprising a reporter gene operably linked to a promoter from a cellular gene in Table 2 A.
  • induction of at least one of the cellular genes in Table 2A is assayed using the recombinant mammalian cell and increased expression of the reporter gene detected in the presence and absence of the compound.
  • the method comprises the additional steps of assaying the mammalian cell in the presence and absence of the test compound for expression of one or more genes in Table 2B; and identifying compounds wherein expression of the genes in Table 2B is not greater in the presence of the compound than in the absence of the compound.
  • Expression of reporter genes according to the method is preferably detected by hybridization to a complementary nucleic acid, by using an immunological reagent or by assaying for an activity of the reporter gene product.
  • the method for identifying a compound that induces senescence in a mammalian cell comprises the steps of culturing the mammalian cell in the presence and absence of the compound; assaying expression of at least one cellular gene set forth in Table 2A in said cell in the presence of the compound with expression of said gene in the cell in the absence of the compound; assaying the recombinant mammalian cell for cell growth and morphological features of senescence; and identifying compounds that induce senescence when expression of at least one cellular gene in Table 2A is higher in the presence of the compound than in the absence of the compound and the cells are growth-inhibited and express morphological features of senescence in the presence of the compound.
  • the mammalian cell is a p53 deficient cell. In other preferred embodiments, the mammalian cell is a tumor cell.
  • the cellular gene is a human gene, most preferably BTG1, BTG2, EPLIN, WLPl, Maspin, MIC-1, IGFBP-6 or amphiregulin. Expression of cellular genes according to the method is preferably detected by hybridization to a complementary nucleic acid, by using an immunological reagent or by assaying for an activity of the cellular gene product.
  • the mammalian cell is a recombinant mammalian cell comprising a reporter gene operably linked to a promoter from a cellular gene in Table 2 A.
  • induction of at least one of the cellular genes in Table 2A is assayed using the recombinant mammalian cell and increased expression of the reporter gene detected in the presence and absence of the compound.
  • the method comprises the additional steps of assaying the mammalian cell in the presence and absence of the test compound for expression of one or more genes in Table 2B; and identifying compounds wherein expression of the genes in Table 2B is not greater in the presence of the compound than in the absence of the compound.
  • Expression of reporter genes according to the method is preferably detected by hybridization to a complementary nucleic acid, by using an immunological reagent or by assaying for an activity of the reporter gene product.
  • the invention provides a method for identifying a compound that induces senescence in a mammalian cell.
  • the method comprises the steps of culturing the mammalian cell in the presence and absence of the compound; assaying expression of at least one cellular gene set forth in Table 1 in said cell in the presence of the compound with expression of said gene in the cell in the absence of the compound; and identifying compounds that induce senescence when expression of at least one cellular gene in Table 1 is lower in the presence of the compound than in the absence of the compound.
  • the mammalian cell is a p53 deficient cell.
  • the mammalian cell is a tumor cell.
  • the cellular gene is a human gene, most preferably HFH-11, STEAP, RHAMM, ENSIG1, LRPR1.
  • Expression of cellular genes according to the method is preferably detected by hybridization to a complementary nucleic acid, by using an immunological reagent or by assaying for an activity of the cellular gene product.
  • the mammalian cell is a recombinant mammalian cell comprising a reporter gene operably linked to a promoter from a cellular gene in Table 1.
  • induction of at least one of the cellular genes in Table 1 is assayed using the recombinant mammalian cell and decreased expression of the reporter gene detected in the presence and absence of the compound.
  • the method comprises the additional steps of assaying the mammalian cell in the presence and absence of the test compound for expression of one or more genes in Table 2B; and identifying compounds wherein expression of the genes in Table 2B is not greater in the presence of the compound than in the absence of the compound.
  • Expression of reporter genes according to the method is preferably detected by hybridization to a complementary nucleic acid, by using an immunological reagent or by assaying for an activity of the reporter gene product.
  • the method for identifying a compound that induces senescence in a mammalian cell comprises the steps of culturing the mammalian cell in the presence and absence of the compound; assaying expression of at least one cellular gene set forth in Table 1 in said cell in the presence of the compound with expression of said gene in the cell in the absence of the compound; assaying the recombinant mammalian cell for cell growth and morphological features of senescence; and identifying compounds that induce senescence when expression of at least one cellular gene in Table 1 is lower in the presence of the compound than in the absence of the compound and the cells are growth-inhibited and express morphological features of senescence in the presence of the compound.
  • the mammalian cell is a p53 deficient cell. In other preferred embodiments, the mammalian cell is a tumor cell.
  • the cellular gene is a human gene, most preferably HFH- 11, STEAP, RHAMM, LNSIG1, LRPR1. Expression of cellular genes according to the method is preferably detected by hybridization to a complementary nucleic acid, by using an immunological reagent or by assaying for an activity of the cellular gene product.
  • the mammalian cell is a recombinant mammalian cell comprising a reporter gene operably linked to a promoter from a cellular gene in Table 1.
  • inhibition of at least one of the cellular genes in Table 1 is assayed using the recombinant mammalian cell and decreased expression of the reporter gene detected in the presence and absence of the compound.
  • the method comprises the additional steps of assaying the mammalian cell in the presence and absence of the test compound for expression of one or more genes in Table 2B; and identifying compounds wherein expression of the genes in Table 2B is not greater in the presence of the compound than in the absence of the compound.
  • Expression of reporter genes according to the method is preferably detected by hybridization to a complementary nucleic acid, by using an immunological reagent or by assaying for an activity of the reporter gene product.
  • the invention provides compounds produced according to the methods of the invention, most preferably embodiments of the methods of the invention whereby the method comprises the additional steps of assaying the mammalian cell in the presence and absence of the test compound for expression of one or more genes in Table 2B; and identifying compounds wherein expression of the genes in Table 2B is not greater in the presence of the compound than in the absence of the compound.
  • the invention in a fourth aspect provides a method for assessing efficacy of a treatment of a disease or condition relating to abnormal cell proliferation or neoplastic cell growth.
  • the method comprises the steps of: obtaining a biological sample comprising cells from an animal having a disease or condition relating to abnormal cell proliferation or neoplastic cell growth before treatment and after treatment; comparing expression of at least one gene in Table 1, 2 A or 2B after treatment with expression of said genes before treatment; and determining that said treatment has efficacy for treating the disease or condition relating to abnormal cell proliferation or neoplastic cell growth if expression of at least one gene in Table 2A and 2B is higher after treatment than before treatment or expression of at least one gene in Table 1 is lower after treatment than before treatment.
  • the biological sample comprises tumor cells.
  • the gene is a cellular gene in Table 2A, most preferably wherein at least one cellular gene is a human gene that is BTG1, BTG2, EPLIN, VvTPl, Maspin, MIC-1, IGFBP-6 or amphiregulin.
  • the gene is a cellular gene in Table 1, most preferably a human gene that is HFH-11, STEAP, RHAMM, LNSIGl, and LRPR1. Expression of cellular genes according to the method is preferably detected by hybridization to a complementary nucleic acid, by using an immunological reagent or by assaying for an activity of the cellular gene product.
  • the invention provides a method for treating a disease or condition relating to abnormal cell proliferation or neoplastic cell growth, most preferably cancer.
  • the method of the invention comprises the steps of administering to an animal having said disease or condition a therapeutically effective amount of a compound produced according to the inventive methods of the invention, most preferably embodiments of the methods of the invention whereby the method comprises the additional steps of assaying the mammalian cell in the presence and absence of the test compound for expression of one or more genes in Table 2B; and identifying compounds wherein expression of the genes in Table 2B is not greater in the presence of the compound than in the absence of the compound.
  • the invention provides methods for detecting secreted proteins produced in senescent cells.
  • the invention in this aspect provides diagnostic methods for determining, inter alia, whether a treatment that induces senescence in cells, preferably tumor cells, is effective.
  • detection assays as provided by the invention are performed on a bodily fluid, such as blood, urine, effusions, ascitic fluid, saliva, cerebrospinal fluid, cervical secretions, vaginal secretions, endometrial secretions, gastrointestinal secretions, bronchial secretions, sputum, or secretions or washings from the breast.
  • the invention provides methods for identifying a compound that inhibits senescence-associated induction of cellular gene expression.
  • the method comprises the steps of contacting the cell with a cytotoxic agent at a concentration of said agent that inhibits cell growth; assaying the cell in the presence and absence of the compound for changes in expression of cellular genes induced when cells become senescent; and identifying the compound as an inhibitor of senescence-associated induction of cellular gene expression if expression of the above cellular genes is induced in the absence of the compound but is not induced in the presence of the compound.
  • the cellular gene is a human gene that is cyclin Dl, serum-inducible kinase, CYR61, prosaposin, transforming growth factor ⁇ (TGF ⁇ ), kallikrein 7, calpain-L2, neurosin, plasminogen activator, urokinase, amyloid beta (A4) precursor protein (jSAPP), or integral membrane protein 2B (BRI/ITM2B).
  • the mammalian cell is a p53 deficient cell.
  • the mammalian cell is a tumor cell. Expression of cellular genes according to the method is preferably detected by hybridization to a complementary nucleic acid, by using an immunological reagent or by assaying for an activity of the cellular gene product.
  • the mammalian cell is a recombinant mammalian cell comprising a reporter gene operably linked to a promoter from a human gene that is cyclin Dl, serum-inducible kinase, CYR61, prosaposin, transforming growth factor ⁇ (TGF ⁇ ), kallikrein 7, calpain-L2, neurosin, plasminogen activator, urokinase, amyloid beta (A4) precursor protein (jSAPP), or integral membrane protein 2B (BRI/ITM2B).
  • a human gene that is cyclin Dl, serum-inducible kinase, CYR61, prosaposin, transforming growth factor ⁇ (TGF ⁇ ), kallikrein 7, calpain-L2, neurosin, plasminogen activator, urokinase, amyloid beta (A4) precursor protein (jSAPP), or integral membrane protein 2B (BRI/ITM2B).
  • the method comprises the steps of contacting the mammalian cell with a cytotoxic agent at a concentration of said agent that inhibits cell growth; assaying the mammalian cell in the presence and absence of the test compound for expression of the reporter gene; and identifying compounds wherein expression of the reporter gene is not greater in the presence of the compound than in the absence of the compound.
  • Expression of the reporter gene according to the method is preferably detected by hybridization to a complementary nucleic acid, by using an immunological reagent or by assaying for an activity of the reporter gene product.
  • the invention also provides methods for monitoring the efficacy of treatment.
  • tumor cells that have become senescent and are no longer able to grow are identified and distinguished from tumor cells that recover and proliferate after treatment.
  • Senescence marker detection in biopsy samples from tumors obtained after patient treatment is used as an indicator of treatment response.
  • Figure 1A is a fluorescence-activated cell sorting (FACS) profile of proliferating and growth-arrested fractions of doxorubicin-treated HCTl 16 cells. Cells are sorted based on PKH2 fluorescence on the indicated days after release from doxorubicin.
  • FACS fluorescence-activated cell sorting
  • PKH2 10 population of proliferating cells appears on day 4 and separates from the PKH2 hl
  • Figure IB is a FACS profile of proliferating and growth-arrested fractions of doxorubicin-treated HCTl 16 cells separated on the basis of DNA content. Exponentially growing HCTl 16 cells have a peak at Gl, while the PKH2 hl population isolated 9 days after drug treatment has a peak at G2/M.
  • Figure 1C is a photograph showing SA- ⁇ -gal staining of PKH2 hl and PKH2 10 populations, separated 6 days after release from the drug. Both panels are photographed at the same 200x magnification.
  • Figure ID is a photograph showing colony formation by PKH2 hl and PKH2 10 populations, separated 9 days after drug treatment and plated at 10,000 live (Pl-negative) cells per 10-cm plate.
  • Figures 2A and 2B are photographs of RT-PCR analysis of changes in the expression of the indicated senescence-associated genes, ⁇ -actin was used as a normalization standard.
  • Figure 2A shows a comparison of gene expression in proliferating (PKH2 10 ) and senescent (PKH2 hi ) populations of HCTl 16 cells, separated 9 days after doxorubicin treatment.
  • Figure 2B is a comparison of gene expression in the unsorted populations of wild-type, p21-/- and p53-/- HCTl 16 cells, before and after 24-hr treatment with 200 nM doxorubicin, and on the indicated days after release from the drug. Genes were designated as p53- or p21 -dependent if changes in their expression became detectable at a later day or were less pronounced in the p53-/- or p21-/- lines than in the wild-type cells.
  • Figures 3 A and 3B are photographs of immunoblotting analysis of changes in p53 and the indicated protein products of genes that show altered expression in drug-induced senescence, ⁇ -actin was used as a normalization standard.
  • Figure 3A shows the results of immunoblotting of wild type HCTl 16 cells that were either untreated, treated for two days with 200 nM doxorubicin, or sorted into proliferating (PKH2 10 ) and senescent (PKH2 hl ) cell populations 9 days after doxorubicin treatment.
  • Figure 3B shows the p53 dependence of p21 induction in doxorubicin-treated HCTl 16 cells, through immunoblotting analysis of the wild type, p21-/- and p53-/- HCTl 16 cell lines treated with doxorubicin for the indicated number of days.
  • This invention provides genes the expression of which is modulated in cells that become senescent upon treatment with cytotoxic agents.
  • the invention also provides methods for identifying compounds that mimic the gene expression modulating properties of cytotoxic agents but lack toxicity that is characteristic of chemo therapeutic drug treatment, as well as the compounds identified by the methods. Diagnostic and therapeutic treatment methods are provided as set forth more particularly herein.
  • the term "senescence” will be understood to include permanent cessation of DNA replication and cell growth not reversible by growth factors, such as occurs at the end of the proliferative lifespan of normal cells or in normal or tumor cells in response to cytotoxic drugs, DNA damage or other cellular insult. Senescence is also characterized by certain morphological features, including increased size, flattened morphology increased granularity, and senescence-associated ⁇ - galactosidase activity (SA- ⁇ -gal).
  • SA- ⁇ -gal senescence-associated ⁇ - galactosidase activity
  • the term "senescence-associated gene” is intended to encompass genes the expression of which is modulated (either induced or repressed) when a cell expresses a senescent phenotype, particularly a senescence phenotype produced by contacting the cells with a cytotoxic agent. Most preferably, the term will be understood to refer to the genes disclosed herein, inter alia, in Tables 1 and 2.
  • Senescence can be conveniently induced in mammalian cells by contacting the cells with a dose of a cytotoxic agent that inhibits cell growth (as disclosed in Chang et al., 1999a, ibid.).
  • Cell growth is determined by comparing the number of cells cultured in the presence and absence, of the agent and detecting growth inhibition when there are fewer cells in the presence of the agent than in the absence of the agent after an equivalent culture period of time
  • cytotoxic agents include but are not limited to doxorubicin, aphidicolin, cisplatin, cytarabine, etoposide, taxol and ionizing radiation. Appropriate dosages will vary with different cell types; the determination of the dose that induces senescence is within the skill of one having ordinary skill in the art, as disclosed in Chang et al, 1999a, ibid.
  • a cell or “cells” is intended to be equivalent, and particularly encompasses in vitro cultures of mammalian cells grown and maintained as known in the art, as well as biological samples obtained, inter alia, from tumor specimens in vivo.
  • cellular genes in the plural is intended to encompass a single gene as well as two or more genes. It will also be understood by those with skill in the art that effects of modulation of cellular gene expression, or reporter constructs under the transcriptional control of promoters derived from cellular genes, can be detected in a first gene and then the effect replicated by testing a second or any number of additional genes or reporter gene constructs. Alternatively, expression of two or more genes or reporter gene constructs can be assayed simultaneously within the scope of this invention.
  • the methods of the invention can be practiced using any mammalian cell, preferably a rodent or primate cell, most preferably a human cell that can develop a senescence phenotype in response to a cytotoxic agent.
  • Preferred cells include mammalian cells, preferably rodent or primate cells, and most preferably human cells.
  • most preferred cells are p53 deficient cells, that are cells expressing less than the normal amount or less than the normal functional activity of tumor suppressor p53 as the result of mutation, deletion, recombination, chromosome loss or genetic manipulation.
  • the methods of the invention are advantageously practiced using recombinant mammalian cells comprising a recombinant expression construct encoding a reporter gene operably linked to a promoter from a gene that is induced in senescent cells.
  • Prefe ⁇ ed reporter genes comprising said constructs include firefly luciferase, chloramphenicol acetyltransferase, beta-galactosidase, green fluorescent protein (GFP), alkaline phosphatase and most particularly a commercially-available GFP- luciferase fusion gene.
  • promoters comprising the recombinant expression constructs of the invention are promoters from a cellular gene known to be induced in senescent cells.
  • the cellular gene promoter is advantageously from a gene identified in Table 2A herein.
  • the cellular promoter is from BTG1, BTG2, EPLIN, WIP1, Maspin, MIC-1, IGFBP-6 or amphiregulin.
  • the cellular gene promoter is from a gene that is repressed in senescent cells.
  • Preferred promoters of this type include promoters is from a gene identified in Table 1 herein.
  • the cellular promoter is from HFH-11, STEAP, RHAMM, LNSIG1, LRPR1.
  • Promoter sequences from some of these genes are known in the art. These include: cyclin Dl (Motokura & Arnold, 1993, Genes Chromosomes Cancer 7: 89-95); CYR61 (Latinkic et al, 1991, Nucleic Acids Res. 19: 3261-7); prosaposin (Sun et al, 1998, Gene 218: 23-34); transforming growth factor ⁇ (TGF ⁇ ; Raja et al, 1991, Mol Endocrinol 5: 514-20); kallikrein 7 (Yousef et al, 2000, Gene 254: 119-128); calpain-L2 (Suzuki et al, 1995, Biol Chem Hoppe Seyler.
  • promoter sequences can be readily isolated from a region of genomic DNA within about 5 kilobases (and more typically within 1 kilobase) upstream of a cDNA encoding the gene.
  • the availability of the complete sequence of the human genome permits the genomic region 5' to any gene to be inspected for consensus promoter sequences, such as AT-rich sequences termed "TATA" boxes, and additional sequences comprising the sequence "CAAT” that are recognized as mediating the interaction of the nucleic acid of the promoter with protein factors such as RNA polymerase.
  • Putative promoters can be readily tested by inserting the putative promoter sequence upstream from a reporter gene and comparing reporter gene activity in such constructs with activity in constructs without the putative promoter insert.
  • Recombinant expression constructs can be introduced into appropriate mammalian cells as understood by those with skill in the art, most preferably transfection and electroporation. Preferred embodiments of said constructs are produced in plasmid vectors or other vectors that can be used to easily produce useful quantities of the vector. Alternative embodiments include transmissible vectors, more preferably viral vectors and most preferably retrovirus vectors, adenovirus vectors, adeno-associated virus vectors, and vaccinia virus vectors, as known in the art. See, generally, MAMMALIAN CELL BIOTECHNOLOGY: A PRACTICAL APPROACH, (Butler, ed.), Oxford University Press: New York, 1991, pp. 57-84. Cells transiently transfected with the recombinant expression construct and more preferably cells stably transfected with the construct and selected using a selective agent are advantageously used in the practice of certain embodiments of the methods of the invention.
  • senescence response in clinical cancers requires diagnostic markers for senescent cells.
  • the most common senescence marker, SA- ⁇ -gal (Dirnri et al, 1995, Proc. Natl. Acad. Sci. USA 92: 9363-9367), has two major disadvantages: it represents an enzymatic activity which is preserved only in frozen tissue samples and for a limited period of time, and it is not mechanistically related to growth arrest of senescent cells.
  • the invention provides a number of genes that are upregulated in senescent cells. These proteins provide sensitive diagnostic markers for cytotoxic agent-induced senescence.
  • EPLIN doxorubicin-treated HCTl 16 cells
  • EPLIN a growth-inhibitory protein that was downregulated in 20 of 21 carcinoma cell lines relative to normal epithelial tissues
  • retinoids is strongly induced in MCF-7 breast carcinoma cells by treatment with retinoids, under the conditions that produce senescence-like growth arrest
  • the invention also provides genes the expression of which is downregulated in cytotoxic agent-induced senescence. These genes are useful for detecting senescence in tumor cells in like manner as genes that are induced during senescence, except that senescence will be marked by downregulation of such genes.
  • genes are of special interest as markers that are downregulated in senescent cells, including HFH-11 (Trident), a transcription factor implicated in cell cycle progression (Ye et al, 1999, Mol. Cell. Biol. 19: 8570-8580), STEAP, a gene overexpressed in different cancers (Hubert et al, 1999, Proc. Natl. Acad. Sci.
  • hybridization assays for detecting cellular nucleic acid, most preferably mRNA, said assays including northern hybridization, Southern hybridization, and any of a variety of in vitro amplification methods known in the art.
  • Gene expression changes can also be detected using immunological reagents and methods, including enzyme-linked immunosorbent assay (ELISA) and other assays using polyclonal or monoclonal antibodies, antibody fragments or recombinant or chimeric antibodies and such immunological reagents.
  • ELISA enzyme-linked immunosorbent assay
  • Activity of specific gene products most preferably used with reporter gene constructs having known and quantifiable activities and most preferably producing easily-detected products are also advantageous for detecting senescence-associated changes in gene expression.
  • Elucidation of molecular changes associated with treatment-induced senescence is also advantageous therapeutically. Permanently arresting tumor cell growth through the induction of accelerated senescence is an attractive treatment approach, since this response to drug treatment can be elicited even under the conditions of minimal cytotoxicity.
  • the instant disclosure that drug-induced senescence is associated with concerted induction of multiple antiprohferative genes (some of which also inhibit the growth of neighboring cells) suggests the existence of common regulatory pathways activating such genes.
  • most of the growth-inhibitory genes are also induced by doxorubicin treatment in p53-deficient cells. Agents that can be developed to stimulate the induction of senescence-associated growth-inhibitory genes are likely therefore to be efficacious against tumors with or without functional p53.
  • the obverse side of drug-induced senescence is the induction of genes associated with pathological conditions (such as Alzheimer's disease), as well as proteases and mitogenic, antiapoptotic and angiogenic secreted factors. Expression of such genes by senescent cells may have potentially adverse effects in the short term (growth stimulation of non-senescent tumor cells) and in the long term (increased likelihood of de novo carcinogenesis and age-related diseases).
  • a linkage between cell senescence and carcinogenesis in vivo has been suggested by a recent study of Paradis et al. (2001, Human Pathol.
  • p21 induction upregulates many disease-associated genes and induces paracrine anti-apoptotic and mitogenic activities (Chang et al, 2000, ibid.), and p21 knockout was shown herein to decrease or delay the induction of such genes as prosaposin, TGF ⁇ and Alzheimer's ⁇ APP.
  • the present invention provides methods for identifying compounds that induce senescence in tumor cells without concomitantly inducing expression of said mitogenic, antiapoptotic and angiogenic secreted factors or genes associated with pathological conditions.
  • the existence of such compounds is suggested by the behavior of retinoids, which induce tumor cell senescence through co-activation of several growth-inhibitory genes but not of p21 or other genes associated with pathological conditions (as disclosed in co-owned and co-pending U.S. Serial No. 09/865,879, filed May 25, 2001, incorporated by reference herein and in Dokmanovic et al, 2002, Cancer Biol. Ther. I: 16-19), and the present invention provides methods to identify other compounds dissociated from cytotoxicity or other confounding features of compounds known in the art to produce senescence in tumor cells.
  • the invention also provides methods for monitoring the efficacy of treatment, by identifying tumor cells that have become senescent and are no longer able to grow and distinguishing said cells from tumor cells that recover and proliferate after treatment.
  • the detection of the markers of senescence in the biopsies of treated tumors can be used as an indicator of treatment response.
  • This type of diagnostics should be useful in many clinical situations, including for example as a biopsy test to evaluate the success of radiation therapy that may potentially require several months or even years for complete response (see Cox et al, 1983, Int. J. Radiat. Oncol. Biol. Phys. 9: 299-303; Bataini et al, 1988, Am. J. Surg. 155: 754-760).
  • the predominance of tumor cells that express markers of senescence is expected to be positively correlated with the success of treatment.
  • Expression of the corresponding genes can be measured at the protein level, using antibodies against the corresponding gene products for in situ immunostaining, enzyme- linked immunosorbent assay (ELISA), or western blotting.
  • Gene expression can also be measured at the nucleic acid level, most preferably by detecting expression of RNA encoding at least one of said genes, using in situ hybridization, in situ RT-PCR, or bulk RNA analysis techniques, such as RT-PCR or different forms of filter hybridization (including northern blotting).
  • the choice of markers that are inhibited in senescent cells is provided by the genes listed in Table 1.
  • senescence markers that are induced in senescent cells are provided by the genes listed in Table 2.
  • Markers inhibited in senescent cells include the genes that are causally involved in cell proliferation and are known to be inhibited in other systems of cell senescence, including for example Ki-67 (which is already widely used as a proliferation marker), CENP-F, AIM-1, MAD-2, ribonucleotide reductase Ml, and thymidine kinase.
  • markers also include genes that show tumor-specific expression and have not been previously shown to be inhibited in senescence, such as STEAP, RHAMM or TLS/FUS.
  • senescence markers are the genes that are induced in senescent cells and are causally involved in cell growth inhibition, including for example BTG1, BTG2, EPLIN, WIPl, Maspin, MIC-1, IGFBP-6 or amphiregulin, and other genes expression of which is downregulated in tumors relative to normal tissues, such as P-cadherin, desmoplakin, desmoyokin, and neurosin.
  • genes that are induced in senescent cells encode secreted proteins that can be detected not only within the affected tissues but also in bodily fluids, such as blood, urine, effusions, ascitic fluid, saliva, cerebrospinal fluid, cervical secretions, vaginal secretions, endometrial secretions, gastrointestinal secretions, bronchial secretions, sputum, or secretions or washings from the breast.
  • secreted proteins include tumor growth inhibitors, and their induction by cancer therapeutic agents should contribute to the success of therapy.
  • Ada 1518: 145-151) and amphiregulin is induced by vitamin D (Akutsu et al, 2001, Biochem. Biophys. Res. Commun. 281: 1051- 1056), but stable induction of these proteins in cells undergoing treatment-induced senescence was not known in the prior art.
  • Antibodies against the above proteins have been developed and many of them are available commercially.
  • anti-Maspin antibody is available from PharMingen, San Diego, CA (Catalog # 554292)
  • anti-amphiregulin antibody is available from Lab Vision Corp., Fremont, CA (Catalog # RB-257-P)
  • anti-IGFBP-6 antibody is available from Cell Sciences, Inc., Norwood, MA (Catalog # PAU1).
  • Monoclonal antibodies against MIC-1 have been described in the art (Fairlie et al, 2001, Biochemistry 40: 65-73). These or similar antibodies can be used most conveniently in an ELISA assay, or in other conventional immunochemical assays, to detect and measure the amount of corresponding proteins.
  • protein levels in blood or urine that correlate with treatment success are not presently known, they can be determined through straightforward clinical studies. In such studies, the corresponding protein levels are measured in patients before treatment and at different time points after the administration of treatment. The results of these measurements are then correlated with standard clinical criteria for treatment success (partial remission and subsequently complete remission).
  • cytotoxic agent-inducible and repressible genes are useful targets for identifying compounds other than cytotoxic agents that mimic the physiologically-based growth inhibitory effect on cell proliferation. Identifying such compounds advantageously provides alternative agents for producing growth arrest in mammalian cells, particularly tumor cells and other cells that proliferate inappropriately or pathogenically. Such compounds are beneficial because they can mimic the growth- inhibitory effects of cytotoxic agents.
  • growth-inhibitory drugs and compounds known in the prior art disadvantageous ⁇ induce p21 gene expression, which induces senescence, growth arrest and apoptosis by activating a plurality of genes, the expression of which is associated with the development of diseases, particularly age- related diseases such as Alzheimer's disease, atherosclerosis, renal disease, and arthritis (as disclosed in co-owned and co-pending U.S. Serial No. 60/265,840, filed February 1, 2001 (Attorney Docket No. 99,216-E) and U.S. Serial No.
  • cytotoxic agent-induced senescence-associated genes with pathogenic activity provides targets for developing drugs that inhibit the induction of such genes.
  • the invention provides methods for assaying test compounds that inhibit induction of senescence-associated genes consequent to cytotoxic agent-induced senescence, by contacting cells with the test compound. Compounds that inhibit induction of these genes show no increased expression of these genes in agent-treated cells compared with untreated cells. Reporter gene constructs are also advantageously used to assay gene induction and lack thereof in the methods of the invention directed to these disease-associated genes.
  • Cytological and gene expression analyses were performed to determine the effects of doxorubicin, a widely used anticancer drug that produces DNA damage by stabilizing a cleavable intermediate complex formed by topoisomerase II in the process of DNA segregation, on human colon cancer cells (HCT 116) in culture.
  • HCTl 16 colon carcinoma cells (Myohanen et al, 1998, Cancer Res. 58: 591-593; Accession No. CCL-247, American Type Culture Collection, Manassas, VA), including wild-type, p21-/- (clone 80S4) and p53-/- (clone 379.2) cell lines (a gift of Dr. B. Vogelstein, Johns Hopkins University) were grown in Dulbecco Modified Eagle Medium with 10% FC2 serum. Cells were plated at 5 x 10 6 cells per 15-cm plate and treated for 24-hr with 200 nM doxorubicin. Thereafter, cells were allowed to recover in drug-free media up to 10 days.
  • FACS fluorescence-activated cell sorter
  • Sorted fractions of senescent (PKH2 hl ) and proliferating (PKH2'°) cells were analyzed for DNA content using propidium iodide (PI) staining and FACS analysis as described by Jordan et al. (1996, Cancer Res. 56: 816-825).
  • the cells were also stained for senescence-associated ⁇ - galactosidase (SA- ⁇ -gal) activity as described by Dimri et al. (1995, Proc. Natl. Acad. Sci. USA 92: 9363-9367).
  • SA- ⁇ -gal senescence-associated ⁇ - galactosidase
  • FIG. 1A Cell proliferation as detected by FACS using PKH2 fluorescence is shown in Figure 1A. Changes in PKH2 fluorescence were monitored by FACS on different days after doxorubicin treatment. Cells that died after drug treatment were excluded from this analysis based on their staining with membrane-impermeable dye PI. Almost all PI- negative cells remained growth-arrested (PKH2 hl ) for the first 2-3 days after doxorubicin treatment, but a proliferating cell population (PKH2 10 ) emerged starting from day 4.
  • RNA and protein extracts were prepared from PKH2 10 and PKH2 hl cell populations, separated in different experiments 6, 9 or 10 days after release from doxorubicin.
  • Fluorescent cDNA probes were synthesized and used for hybridization with the Human UniGEM V 2.0 cDNA microarray and signal analysis (assays were conducted by IncyteGenomics, St. Louis, MO, as described at that company's web site, www.incyte.com). Changes in gene expression were verified by semi-quantitative reverse transcription-PCR (RT-PCR), essentially as described (Noonan et al, 1990, Proc. Natl. Acad. Sci.
  • RT-PCR semi-quantitative reverse transcription-PCR
  • Fluorescent cDNA probes were prepared from RNA of senescent (PKH2 hl ) and proliferating (PKH2 10 ) cell populations and used for differential hybridization with UniGEM V 2.0 human cDNA microarray (IncyteGenomics, Inc.), containing >9,000 genes. 82% of the more than 9,000 sequence-verified genes and expressed sequence tags (ESTs) present in the UniGem V 2.0 microarray gave measurable hybridization signals with both probes.
  • More than one half of 68 genes and ESTs downregulated in senescent cells are known to play a role in cell cycle progression: 25 of these genes are involved in different stages of mitosis or DNA segregation (e.g., CDC2, Ki-67, MAD2, Topoisomerase Il ⁇ ); 11 genes function in DNA replication and chromatin assembly (e.g. ribonucleotide reductase Ml, thymidylate kinase, replication protein A3); and 4 genes are involved in DNA repair (e.g. HEX1, FEN1). Downregulation of genes involved in cell proliferation correlates with the growth-arrested state of senescent cells and demonstrates the biological relevance of gene expression profiling in our system.
  • 25 of these genes are involved in different stages of mitosis or DNA segregation (e.g., CDC2, Ki-67, MAD2, Topoisomerase Il ⁇ ); 11 genes function in DNA replication and chromatin assembly (e.g. ribonucleotide reduct
  • HCTl 16 cells were found to upregulate multiple genes with documented growth-inhibitory activity, providing an ample explanation for the maintenance of doxorubicin-induced cell cycle arrest in the absence of pi 6 (which is not expressed in HCT 116 cells).
  • One of the upregulated genes is p21 (shown in Figure 2A).
  • Analysis of p21 and p53 protein induction by doxorubicin in wild type, p53-/- (14) and p21-/- (15) HCTl 16 cell lines demonstrated that p21 induction in this system is strongly dependent on p53 (shown in Figure 3B).
  • Both p53 and p21 proteins are maintained at elevated levels in senescent cells isolated 9 days after release from the drug (Figure 3A). In contrast to p21, however, p53 is upregulated only at the protein level. In addition to sustained p21 induction, senescent cells strongly overexpress many other growth inhibitors, including several known or putative tumor suppressor genes. Some of these genes encode intracellular growth-inhibitory proteins, including tumor suppressor BTG1 and its homolog BTG2, putative tumor suppressor EPLIN (Epithelial Protein Lost in Neoplasm) and WLPl phosphatase.
  • Senescent HCTl 16 cells also overexpress several secreted growth inhibitors, including MIC-1 (pTGF- ⁇ ), insulin-like growth factor binding protein-6 (IGFBP-6), serine protease inhibitor Maspin (a tumor suppressor downregulated in advanced breast cancers), and amphiregulin, an EGF-related factor that inhibits proliferation of several carcinoma cell lines while promoting the growth of normal epithelial cells.
  • MIC-1 pTGF- ⁇
  • IGFBP-6 insulin-like growth factor binding protein-6
  • Maspin serine protease inhibitor
  • amphiregulin an EGF-related factor that inhibits proliferation of several carcinoma cell lines while promoting the growth of normal epithelial cells.
  • senescent HCTl 16 cells induce several other genes that are downregulated in cancers relative to normal epithelial cells (including MIC-1, P-cadherin, desmoplakin, desmoyokin, neurosin).
  • senescent cells downregulate not only multiple genes involved in cell proliferation but also some other genes that have oncogenic activity (RHAMM and TLS/FUS) or show tumor-specific expression (STEAP).
  • RHAMM and TLS/FUS tumor-specific expression
  • Another sign of putative "normalization" of senescent cells is the upregulation of six members of the keratin gene family.
  • senescent HCTl 16 cells show increased expression of genes for secreted mitogenic, anti-apoptotic and angiogenic factors, such as extracellular matrix (ECM) proteins Cyr ⁇ l and prosaposin, and transforming growth factor ⁇ (TGF- ⁇ ).
  • ECM extracellular matrix
  • TGF- ⁇ transforming growth factor ⁇
  • Induction of such genes results in paracrine activities, which promote tumor cell growth in vitro and in vivo.
  • Such activities have been previously associated with replicative senescence (Campisi, 2000, In vitro 14: 183- 188) in normal cells, and with p21 induction in tumor cells (Chang et al, 2000, Proc. Natl. Acad. Sci. USA 97: 1497-150117).
  • Senescent HCT 116 cells also upregulate several proteases (kallikrein-7, calpain L2, neurosin, urokinase-type plasminogen activator) that may potentially contribute to metastatic growth.
  • proteases kallikrein-7, calpain L2, neurosin, urokinase-type plasminogen activator
  • Several other genes induced in senescent HCT 116 cells are involved in cell adhesion and cell-cell contact (including P-cadherin, Mac2-binding protein and desmoplakin).
  • Other induced genes encode ECM receptors, including several integrins and syndecan-4 (ryudocan), involved in angiogenesis.
  • transmembrane proteins induced in senescent cells are growth-regulatory proteins CD44 and Jagged- 1, Alzheimer's ⁇ -amyloid precursor protein ( ⁇ APP), and another amyloid precursor, BRI, associated with an Alzheimer-like disease.
  • ⁇ APP Alzheimer's ⁇ -amyloid precursor protein
  • BRI amyloid precursor
  • genes that are differentially expressed in doxorubicin-treated HCT 116 cells are genes encoding known or putative transcription factors or co factors. Genes for several known or putative transcription factors and cofactors show altered regulation in the senescent HCTl 16 cells.
  • One of the downregulated transcription factors is winged helix protein HFH-11 (Trident), a positive regulator of DNA replication, that is specifically expressed in cycling cells (Ye et al, 1999, Mol. Cell. Biol. 19: 8570-8580).
  • HFH-11 winged helix protein HFH-11
  • Several upregulated transcription factors are related to the AP-1 family, which mediates cellular responses to various mitogenic signals, interferons and different forms of stress (Wisdom, 1999, Exp. Cell. Res. 253: 180-185).
  • c-Jun and two other basic leucine zipper proteins include c-Jun and two other basic leucine zipper proteins, XBP-1 (structurally related to c-Jun) and ATF3 that dimerizes with c-Jun.
  • XBP-1 structurally related to c-Jun
  • ATF3 that dimerizes with c-Jun.
  • Sustained upregulation of ATF3 mRNA and protein in senescent cells is surprising, since induction of this stress-responsive factor is usually transient (over hours), due to the ability of ATF3 to inhibit its own transcription (Wolfgang et al, 2000, J. Biol Chem. 275: 16865-16870).
  • Another induced transcription factor is ELF-1, a member of Ets family of helix-loop-helix proteins that are known to interact functionally, and possibly physically, with AP-1 (Wisdom, ibid.).
  • the observed pattern of gene expression in cytotoxic drug-induced senescence of HCTl 16 cells showed many similarities to senescence in normal cells. Some of the general properties of senescent cells (other than terminal growth a ⁇ est) are resistance to apoptosis, increased cell adhesion (associated with overproduction of ECM components), and secretion of proteases, protease inhibitors, and mitogenic factors (Campisi, ibid.). Genes involved in all of these phenomena are amply represented among those that are upregulated in senescent HCT 116 tumor cells.
  • senescent HCTl 16 cells don't upregulate pl6 or tumor suppressor PML associated with RAS-induced accelerated senescence (Pearson et al, 2000, Nature 406: 207-210).
  • p53 A prominent class of p53 -induced genes encode secreted growth-inhibitory factors, providing paracrine antiprohferative activity (Komarova et al, ibid.).
  • p21 is not a transcriptional regulator per se, but it interacts with a broad network of transcription factors, cofactors and mediators of signal transduction (Dotto, 2000, Biochim. Biophys. Acta 1471 : M43-M56).
  • Overexpression of p21 in fibrosarcoma cells results in downregulation of multiple cell proliferation genes and upregulation of many ECM components and secreted mitogenic and antiapoptotic factors, providing the corresponding activities in conditioned media of p21 -induced cells (Chang et al, 2000, ibid.).
  • a known mechanism for transcription activation by p21 is based on its ability to stimulate p300/CBP transcription cofactors (Snowden et al, 2000, Mol. Cell. Biol. 20: 2676-2686).
  • HCTl 16 cells express a dominant mutant form of transcription factor p300 (Gayther et al, 2000, Nat. Genet. 24: 300-303), which may explain why senescent HCTl 16 cells upregulate a relatively small number of p21-inducible genes.
  • Senescence-associated changes in the expression of most of these genes became detectable in the total population of wild-type HCTl 16 cells after one-day doxorubicin treatment or one day after release from the drug.
  • This early response made it possible to evaluate the effects of p21 and p53 knockouts on total populations of doxorubicin-treated cells, without having to purify the small senescent fractions of p21-/- and p537- cell lines.
  • This group includes transcription factors of the AP-1 family, CYR61, and several intracellular (BTG2, WIPl) and secreted growth inhibitors (Maspin, MIC-1, amphiregulin). None of these genes, however, are completely dependent on p53 for their induction, and all of them are induced in p53-/- cells two days after release from the drug. Almost all senescence-associated growth inhibitors (except for p21 and EPLIN) are eventually induced in p53-/- cells to a level comparable to the wild-type cell line ( Figure 2B). These results provide an explanation for the diminished but still substantial induction of senescence-like growth a ⁇ est in p53-/- cells after doxorubicin treatment (Chang et al, 1999a, ibid.).
  • genes identified herein can be used as markers for assessing compounds for their effects on cellular senescence and also for identifying compounds that induce the senescence phenotype by mechanisms that do not implicate p53, p21 or both.
  • a cell-based screening assay is used to identify compounds that activate senescence-associated growth-inhibitory genes in p53-deficient tumor cells, without concurrent activation of secreted tumor-promoting factors.
  • promoter constructs of different senescence-associated growth-inhibitory genes are constructed that drive expression of a chimeric GFP-luciferase reporter.
  • Such a chimeric reporter was shown to be suitable for selection based on GFP fluorescence and for sensitive promoter activity measurements based on luciferase chemiluminescence (Kotarsky et al, 2001, Anal. Biochem. 288: 209-215).
  • a similar chimeric reporter gene is commercially- available (Clontech, Palo Alto, CA).
  • the promoter-reporter constructs are tested for inducibility by doxorubicin under conditions that activate the co ⁇ esponding genes.
  • the best-regulated promoter constructs are used to develop stably transfected cell lines, and cell lines identified that have the strongest induction of the reporter gene under conditions of drug-induced senescence.
  • HTS high throughput screening
  • This HTS assay is used to screen a chemical compound library (such as the Diversity Set of 1,990 compounds from the Developmental Therapeutics Program (DTP) of NCI). Positive compounds in this assay are then tested for their effects on expression of other genes associated with positive and negative aspects of accelerated senescence. Seven senescence-associated growth-inhibitory genes are preferential targets for induction assays:
  • BTG1 is a tumor suppressor rea ⁇ anged in t(8;12)(q24;q22) chromosomal translocation of B-cell leukemia and an inhibitor of cell proliferation (Rouault et al, 1992, EMBO J. U : 1663-1670). BTG1 was shown to be induced by DNA damage in different human tumor cell lines (Cortes et al, 2000, Mol. Carcinog.
  • BTG2 (PC3/TIS21) is a BTG1 related antiprohferative gene (Rouault et al, 1996, Nat. Genet. 14: 482-486). BTG1 is stress-responsive (Fiedler et al, 1998, Biochem. Biophys. Res. Commun. 249: 562-565) and is also induced in different cell lines by DNA damage, growth factors and tumor promoters (Fletcher et al, 1991, J. Biol. Chem. 266: 14511-14518).
  • IGFBP-6 IGF-binding protein 6
  • doxorubicin a secreted inhibitor of IGF function and tumor cell growth
  • Amphiregulin is an EGF-related factor that was shown to inhibit the growth of several carcinoma cell lines, while promoting the growth of normal epithelial cells (Plowman et al, 1990, Mol. Cell Biol. 10: 1969-1981). Amphiregulin is the major target of transcriptional induction by WT1 Wilms tumor suppressor gene (Lee et al, 1999, Cell 98: 663-673) and is inducible by vitamin D3 (Akutsu et al, 2001,
  • MIC-1 (pTGF- ⁇ /PLAB/PDF/GDF15), a secreted growth-inhibitory member of TGF- ⁇ superfamily, was shown to be induced by p53 at the level of transcription (Tan et al, 2000, Proc. Natl. Acad. Sci. USA 97: 109-114) and was suggested to be a key mediator of paracrine growth-inhibiting effects of p53 (Kannan et al, 2000, FEBS Lett. 470: 77-82). Surprisingly, MIC-1 induction by doxorubicin shows only weak dependence on p53.
  • Maspin a secreted serine protease inhibitor
  • Maspin shows very strong induction by DNA damage at the protein level, in doxorubicin-treated HCTl 16 cells, and others; Zou et al. (2000, J. Biol. Chem. 275: 6051-6054) showed maspin induction by drug treatment in four other tumor cell lines.
  • Maspin expression is induced at the transcriptional level by p53 (Zou et al, ibid.). Although p53 knockout strongly decreases Maspin induction by doxorubicin, such induction is still readily detectable in p53-/- cells.
  • EPLIN Epidermal Protein Lost in Neoplasms
  • an actin-binding cytoskeletal protein is expressed in almost all normal epithelial tissues but downregulated in 20 of 21 tested carcinoma cell lines.
  • EPLIN inhibits cell proliferation, making it a putative tumor suppressor (Maul & Chang, 1999, Oncogene 18: 7838-7841).
  • EPLIN is induced not only in the senescent population of doxorubicin-treated HCTl 16 cells, but also in MCF7 breast carcinoma cells that undergo senescencelike growth a ⁇ est upon treatment with retinoids.
  • EPLIN shows the weakest induction by doxorubicin in the unsorted cells; this induction is even further diminished in p21-/- and p53-/- cells.
  • BTG1 (Rodier et al, 1999, Exp. Cell Res. 249: 337-348), BTG2 (Fletcher et al, 1991, ibid.), IGFBP-6 (Dailly et al, 2001, ibid.), amphiregulin (Lee et al, 1999, ibid.), Maspin (Zou et al, 2000, ibid.), MIC-1 (Tan et al, 2000, ibid.), EPLIN (Gao et al, 2000, J. Cell Physiol.
  • EPLIN has two alternative promoters; the prefe ⁇ ed promoter is the promoter co ⁇ esponding to the longer ⁇ isoform that is preferentially expressed in HCTl 16 and MCF7 cells. Transcription of the co ⁇ esponding genes is regulated by various factors (DNA damage, serum, differentiating agents, phorbol esters, tumor suppressors) through c ⁇ -regulatory elements in their promoters. In addition, Maspin has been shown to be silenced in breast cancers at the level of promoter methylation (Domann et al, 2000, ibid.). Thus, it can be expected that senescence-associated changes in the expression of these genes will be reproducible in promoter constructs.
  • Reporter gene constructs are prepared by traditional cloning methods or by polymerase chain reaction (PCR) amplification of promoter sequences using primers designed from sequences flanking the co ⁇ esponding promoters and human genomic DNA as a template.
  • the promoter sequences are cloned upstream of a suitable reporter gene, the most convenient of which is useful both as a selectable marker and as the basis for HTS.
  • a commercially-available reporter comprising a chimera of green fluorescence protein and luciferase is most suitable for this purpose.
  • This reporter is a chimeric protein formed by the Enhanced form of Green Fluorescent Protein (GFP) (commercially- available from Clontech) at the amino terminal end, fused with firefly luciferase at the carboxyl terminus. This chimeric reporter provides strong GFP fluorescence and high sensitivity of luciferase-based chemiluminescence assays.
  • GFP Green Fluorescent Protein
  • This gene is cloned into a promoterless vector in an orientation that a convenient cloning site or multiple cloning site is operably linked at the 5' end of the reporter gene, so that the promoters from the seven senescence-associated genes can be easily inserted into and thereby operably linked to the reporter gene.
  • p53-deficient cell lines will be used for screening.
  • the primary cell line is a p53-/- derivative of HCTl 16 colon carcinoma cells (Bunz et al, 1998, Science 282: 1497-1501), as described above.
  • promoter constructs that show positive results in this cell line are then tested in other p53-deficient tumor cell types, to confirm that the induction of these promoters is not unique to HCTl 16 cells (damage- responsiveness in a number of cell lines has already been demonstrated for BTGl, BTG2 and Maspin, and retinoid inducibility in breast carcinoma lines was shown for EPLIN and IGFBP-6).
  • p53-mutated tumor cell lines are used, particularly those cell lines that develop the senescent phenotype upon doxorubicin treatment, including SW480 colon carcinoma, U251 glioma and Saos2 osteosarcoma (as disclosed by Chang et al, 1999b, ibid.).
  • Also used in these assays is a derivative of HT1080 fibrosarcoma wherein p53 function has been fully inhibited with a p53-derived genetic suppressor element GSE56 (as disclosed by Chang et al, 1999a, ibid.).
  • promoter-reporter constructs are used initially in transient transfection assays for the induction of luciferase activity by doxorubicin treatment.
  • the tested constructs are mixed with a construct ca ⁇ ying a different reporter gene under a constitutively expressed promoter (e.g. ⁇ -galactosidase transcribed from the CMV promoter).
  • a constitutively expressed promoter e.g. ⁇ -galactosidase transcribed from the CMV promoter.
  • the activity of firefly luciferase and the control reporter gene ( ⁇ -gal) are determined using commercially available assay kits, and the normalized values of firefly luciferase activity are compared between the treated and untreated cells.
  • the promoter constructs that provide the highest expression and the best induction are determined from these assays.
  • promoter constructs showing at least 3-fold induction in transient transfection assays are transfected into p53-/- HCTl 16 cells, and stably transfected cell lines selected with puromycin. About 100 clonal transfectants from each tested construct are isolated and expanded to the size of close to 100,000 cells. At this stage, the picked lines are screened for activity by doxorubicin in 96-well plate assays (as described in more detail below). The best-inducible cell lines are expanded and subsequently characterized by repeated testing for both GFP and luciferase induction.
  • Reporter cell lines are selected to maximize the absolute level of induced luciferase expression while retaining a high fold-induction, because high absolute luciferase expression minimizes the number of cells required to produce a detectable signal in HTS assays.
  • these optimal cell lines are analyzed with regard to the time course and doxorubicin dose- dependence of reporter expression and tested to verify senescence-specificity of the expression. The latter analysis is performed by labeling cells with PKH26 (a fluorophore related to PKH2 but having a red-shifted emission wave length), followed by doxorubicin treatment and release into drug-free media.
  • PKH26 a fluorophore related to PKH2 but having a red-shifted emission wave length
  • PKH26 and GFP fluorescence are analyzed with FACS by two-color analysis for PKH26 and GFP fluorescence.
  • GFP fluorescence selectively associated with PKH26 hl (senescent) cells is thereby determined without physical sorting.
  • reporter expression inducibility in the selected cell lines is tested with senescence-inducing agents other than doxorubicin, other agents, such as ionizing radiation, cisplatin, aphidicolin or cytarabine (Chang et al, 1999b, ibid).
  • the primary reporter cell line for subsequent compound screening is generated thereby, and secondary cell lines expressing the reporter from the promoters of different genes can be used for confirmatory assays.
  • the primary reporter cell line developed as described above is used to develop
  • the dual GFP-luciferase nature of the reporter gene is especially convenient for conducting screening assays using the more sensitive luciferase-based chemiluminescence assay, and the GFP fluorescence to confirm that the effect of a tested compound is not due to artifactual influence on the luciferase assay.
  • the plates are read (with no further manipulations) in the fluorescence reader, to identify the wells with substantial increase in GFP activity.
  • the same plates are then processed for luciferase assay and read in a microplate luminometer. Luminometer readings on three plates are used to identify candidate positives, and compared with the results of GFP fluorescence. Positive compounds are re-tested in another set of assays prior to secondary screening.
  • the nature of the assays for increased luciferase and GFP activity which need to be expressed in live cells over the course of the assay, should eliminate highly cytotoxic compounds from the list of candidates.
  • Compounds that score as positive in the primary analysis are tested for their effect on the expression of different senescence-associated genes. Some of these assays are carried out using stably transfected cell lines, where the reporter gene is driven by promoters of other genes than the one in the primary reporter line. These simple reporter activation assays are wa ⁇ anted if a very large number of positives are detected in the primary assay. A second reporter line can be used to limit the number of compounds to those that are active with more than one promoter. If the number of positive compounds after the primary screen is low, however, this secondary screening step is unnecessary and the positive compounds are used for direct analysis of the compounds on gene expression.
  • RNA is extracted before and after treatment, and expression of different senescence-associated genes is analyzed, for example by quantitative RT-PCR (as disclosed by Noonan et al, 1990) that allows expression levels for multiple genes among a set of RNA samples to be compared.
  • a single RT-PCR assay uses about 50 ng of total cellular RNA, which makes it possible to cany out about 100 assays starting from 5 ⁇ g of total RNA, an amount that is typically used for a single lane in northern hybridization.
  • ⁇ -actin is used as a normalization standard, since its expression is unaltered in senescent cells, according to northern and western blots.
  • RT-PCR primers and assay conditions for 63 genes that are up- or downregulated in doxorubicin-induced accelerated senescence are disclosed in Table 3. These assays are used to test if the positive compounds can activate not only the growth-inhibitory genes that are described above, but also other senescence-associated growth regulators, such as WIPl, CD44, Jagged 1, and also several genes that are known to be downregulated in cancers relative to normal cells and then upregulated in senescent tumor cells, such as P-cadherin, desmoplakin and desmoyokin.
  • senescence-associated growth inhibitors that are downregulated in cancers (such as EPLIN or Maspin).
  • cancers such as EPLIN or Maspin.
  • compounds will be found that will not induce p21 or the potentially pathogenic proteins that are upregulated in doxorubicin-induced senescence, such as secreted tumor-promoting factors TGF ⁇ , CYR61 and prosaposin, proteases such as kallikrein-7 or calpain L2, and plaque- forming proteins, such as Alzheimer's ⁇ -amyloid precursor and BRI.
  • Positive compounds are also assayed for the effects of the compounds on genes that are downregulated in senescent cells, such as tumor-specific transmembrane protein STEAP, and genes involved in cell proliferation (e.g. Ki-67, Topoisomerase Il ⁇ , CDC2, PLK1, MAD2, Thymidylate synthetatse, Ribonucleotide reductase Ml). Inhibition of the latter genes will be indicative of a cytostatic effect of the tested compound, which will be tested in separate assays (see below).
  • genes that are downregulated in senescent cells such as tumor-specific transmembrane protein STEAP
  • genes involved in cell proliferation e.g. Ki-67, Topoisomerase Il ⁇ , CDC2, PLK1, MAD2, Thymidylate synthetatse, Ribonucleotide reductase Ml. Inhibition of the latter genes will be indicative of a cytostatic effect of the tested compound, which will be tested in separate assays
  • analyses are performed to determine how the compound affects cell growth. This analysis will be carried out both by standard cell proliferation assays, and by an assay that evaluates the cytostatic and cytotoxic components of the antiprohferative effect.
  • cells are labeled with PKH2 , treated with the test compound either continuously or for a limited period of time (e.g. 24 hrs), and analyzed after the period of time co ⁇ esponding to three cell doublings.
  • PI propidium iodide
  • the stained cells are then analyzed by FACS for changes in PKH2 fluorescence and for the fraction of Pi-positive cells, next to the control sample of untreated cells that were labeled with PKH2 at the same time.
  • Increased PKH2 fluorescence relative to control cells indicates the inhibition of cell division (cytostatic effect) and increased PI+ fraction indicates the cytotoxic effect.
  • Compounds with preferentially cytostatic (rather than cytotoxic) effect on tumor cells are of particular interest, because such an effect is expected from the specific activation of the senescence program.
  • a prototype compound with desired properties is found, a library of derivatives from this compound is prepared, which is then screened to find more effective agents. Such agents are evaluated as prototype drugs by preclinical studies.
  • genes are induced by treatment with cytotoxic drugs that have been associated with diseases of aging and paracrine growth- stimulating effects, especially tumor cell growth stimulation.
  • These genes include cyclin Dl, serum-inducible kinase, CYR61, prosaposin, transforming growth factor ⁇ (TGF ⁇ ), kallikrein 7, calpain-L2, neurosin, plasminogen activator, urokinase, amyloid beta (A4) precursor protein (/3APP), and integral membrane protein 2B (BRI/ITM2B).
  • Promoters from these genes can be used to make reporter gene constructs in like manner as disclosed in Example 4 for other senescence-associated genes. These constructs can then be used to assay reporter gene induction by cytotoxic drug treatment in the presence and absence of a test compound. Functional promoter sequences have been published for all of these genes: cyclin Dl, serum-inducible kinase, CYR61, prosaposin, transforming growth factor ⁇ (TGF ⁇ ),
  • Dl (Motokura & Arnold, 1993, Genes Chromosomes Cancer 7: 89-95); CYR61 (Latinkic et al, 1991, Nucleic Acids Res. 19: 3261-7); prosaposin (Sun et al, 1998, Gene 218: 23- 34); transforming growth factor (TGF ⁇ ; Raja et al, 1991, Mol. Endocrinol. 5: 514-20); kallikrein 7 (Yousef et al, 2000, Gene 2M: 119-128); calpain-L2 (Suzuki et al, 1995, Biol Chem Hoppe Seyler.
  • Reporter gene constructs are prepared by modification of the methods described in
  • Example 4 Senescence is induced in transient and stably-transfected cells, typically by contacting the cells with a senescence-inducing concentration of doxorubicin or other cytotoxic agent. These experiments are used to establish levels of reporter gene induction in the absence of a test compound.
  • the promoter-reporter constructs are tested for inducibility by doxorubicin under conditions that activate the co ⁇ esponding genes.
  • the best-regulated promoter constructs are used to develop stably transfected cell lines, and cell lines identified that have the strongest induction of the reporter under the conditions of drug treatment, as described in Example 4. Experiments are also performed in the presence of a test compound in an identical manner as experiments performed in the absence of the test compound.
  • Experiments are typically performed at a variety of concentrations of the test compound in cells induced with the same concentration of cytotoxic agent, and expression of the reporter gene determined and compared to reporter gene expression in cells induced with that concentration of cytotoxic agent in the absence of the test compound.
  • results of these experiments identify test compounds that reduce, inhibit or prevent senescence-associated induction of disease-promoting senescence-associated genes in cells treated with a cytotoxic drug, and effective concentrations thereof. These results provide compounds useful for preventing induction of disease-promoting, particularly tumor cell growth-stimulating genes as a consequence of cytotoxic agent- induced senescence associated with conventional cancer treatments.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des gènes de sénescence des tumeurs qui sont induits par le traitement avec des agents cytotoxiques. Cette invention porte sur des réactifs et des méthodes qui permettent d'identifier des composés induisant l'expression de ces gènes cellulaires et produisant la sénescence des cellules, notamment la sénescence des cellules tumorales. Dans cette invention, les réactifs sont des cellules de mammifère de recombinaison qui contiennent des constructions d'expression de recombinaison qui expriment un gène reporteur sous le contrôle transcriptionnel d'un promoteur d'un gène dont l'expression est modulée dans les cellules sénescentes, et les méthodes d'utilisation de telles cellules permettent d'identifier des composés qui modulent l'expression desdits gènes cellulaires.
PCT/US2003/020425 2002-07-03 2003-06-27 Reactifs et methodes d'identification et de modulation de l'expression de genes de senescence des tumeurs WO2004005462A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MXPA05000159A MXPA05000159A (es) 2002-07-03 2003-06-27 Reactivos y metodos para identificar y modular la expresion de genes de senescencia del tumor.
CA002491143A CA2491143A1 (fr) 2002-07-03 2003-06-27 Reactifs et methodes d'identification et de modulation de l'expression de genes de senescence des tumeurs
JP2004519674A JP2006500920A (ja) 2002-07-03 2003-06-27 腫瘍老化遺伝子の発現を同定および調節するための試薬および方法
EP03739349A EP1572932A4 (fr) 2002-07-03 2003-06-27 Reactifs et methodes d'identification et de modulation de l'expression de genes de senescence des tumeurs
US10/520,142 US20070128596A1 (en) 2002-07-03 2003-06-27 Reagents and methods for identifying and modulating expression of tumor senescence genes
AU2003245743A AU2003245743A1 (en) 2002-07-03 2003-06-27 Reagents and methods for identifying and modulating expression of tumor senescence genes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39412102P 2002-07-03 2002-07-03
US60/394,121 2002-07-03

Publications (2)

Publication Number Publication Date
WO2004005462A2 true WO2004005462A2 (fr) 2004-01-15
WO2004005462A3 WO2004005462A3 (fr) 2006-09-14

Family

ID=30115679

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/020425 WO2004005462A2 (fr) 2002-07-03 2003-06-27 Reactifs et methodes d'identification et de modulation de l'expression de genes de senescence des tumeurs

Country Status (8)

Country Link
US (1) US20070128596A1 (fr)
EP (1) EP1572932A4 (fr)
JP (2) JP2006500920A (fr)
KR (1) KR20050039828A (fr)
AU (1) AU2003245743A1 (fr)
CA (1) CA2491143A1 (fr)
MX (1) MXPA05000159A (fr)
WO (1) WO2004005462A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007023808A1 (fr) * 2005-08-23 2007-03-01 Fancl Corporation Marqueur de vieillissement de la peau et technique d'utilisation de celui-ci
JP2008514946A (ja) * 2004-09-29 2008-05-08 プロティオーム・サイエンシィズ・ピーエルシー アルツハイマー病に関する方法及び組成物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6083559B2 (ja) * 2009-07-31 2017-02-22 クロモセル コーポレーション 細胞運命の修飾因子を同定および検証するための方法および組成物
US9354240B2 (en) 2011-03-16 2016-05-31 Tohoku University Probe for analyzing biological tissue and method for utilizing same
EP3540045A1 (fr) 2013-02-01 2019-09-18 Tohoku University Procédé de séparation de cellules d'un tissu biologique

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6007989A (en) * 1992-05-13 1999-12-28 Board Of Regents, The University Of Texas System Methods of screening for compounds that derepress or increase telomerase activity
US6025194A (en) * 1997-11-19 2000-02-15 Geron Corporation Nucleic acid sequence of senescence asssociated gene
US20030180707A1 (en) * 2000-05-26 2003-09-25 Roninson Igor B. Reagents and methods for identifying and modulating expression of genes regulated by retinoids

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040058320A1 (en) * 2000-12-21 2004-03-25 Roninson Igor B. Reagents and methods for identifying and modulating expression of tumor senescence genes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6007989A (en) * 1992-05-13 1999-12-28 Board Of Regents, The University Of Texas System Methods of screening for compounds that derepress or increase telomerase activity
US6025194A (en) * 1997-11-19 2000-02-15 Geron Corporation Nucleic acid sequence of senescence asssociated gene
US20030180707A1 (en) * 2000-05-26 2003-09-25 Roninson Igor B. Reagents and methods for identifying and modulating expression of genes regulated by retinoids

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHANG ET AL.: 'A Senescence-linke Phenotype Distinguishes Tumor Cells That Undergo Terminal Proliferation Arrest after Exposure to Anticancer Agents' CANCER RESEARCH vol. 59, 1999, pages 3761 - 3767, XP002245658 *
CHANG ET AL.: 'Molecular determinants of terminal growth arrest induced in tumor cells by a chmotherapeutic agent' PNAS vol. 99, no. 1, 08 January 2002, pages 389 - 394, XP002903666 *
RONINSON: 'Tumor senescence as a determinant of drug response in vivo' DRUG RESISTANCE UPDATES vol. 5, 2002, pages 204 - 208, XP003001082 *
See also references of EP1572932A2 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008514946A (ja) * 2004-09-29 2008-05-08 プロティオーム・サイエンシィズ・ピーエルシー アルツハイマー病に関する方法及び組成物
WO2007023808A1 (fr) * 2005-08-23 2007-03-01 Fancl Corporation Marqueur de vieillissement de la peau et technique d'utilisation de celui-ci
US7972788B2 (en) 2005-08-23 2011-07-05 Fancl Corporation Skin aging marker and technique for use thereof

Also Published As

Publication number Publication date
EP1572932A2 (fr) 2005-09-14
US20070128596A1 (en) 2007-06-07
MXPA05000159A (es) 2005-09-30
WO2004005462A3 (fr) 2006-09-14
AU2003245743A1 (en) 2004-01-23
KR20050039828A (ko) 2005-04-29
JP2006500920A (ja) 2006-01-12
CA2491143A1 (fr) 2004-01-15
EP1572932A4 (fr) 2008-05-14
JP2009077714A (ja) 2009-04-16

Similar Documents

Publication Publication Date Title
US20090208935A1 (en) Reagents and methods for identifying and modulating expression of tumor senescence genes
Fujita et al. p53 isoforms Δ133p53 and p53β are endogenous regulators of replicative cellular senescence
Zhou et al. Overexpression of human pituitary tumor transforming gene (hPTTG), is regulated by β‐catenin/TCF pathway in human esophageal squamous cell carcinoma
Massion et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis
Lanza et al. Immunohistochemical pattern of MLH1/MSH2 expression is related to clinical and pathological features in colorectal adenocarcinomas with microsatellite instability
Roninson Tumor cell senescence in cancer treatment
Karenko et al. Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue
CA2392495A1 (fr) Reactifs et procedes d'identification et de modulation de l'expression de genes regules par les inhibiteurs de cdk
Zhang et al. CRISPR/Cas9-mediated knockout of the PDEF gene inhibits migration and invasion of human gastric cancer AGS cells
AU2002248262A1 (en) Reagents and methods for identifying and modulating expression of tumor senescence genes
JP2009077705A (ja) Ｃｄｋ阻害剤によって調節される遺伝子発現を同定及び調節するための試薬及び方法
JP2009077714A (ja) 腫瘍老化遺伝子の発現を同定および調節するための試薬および方法
Konstantinidou et al. Reduced retinoblastoma gene protein to Ki-67 ratio is an adverse prognostic indicator for ovarian adenocarcinoma patients
WO2003073062A2 (fr) Reactifs et methodes d'identification et de modulation de l'expression genique regulee par les inhibiteurs de la cdk
Bradley et al. The expression of p53-induced protein with death domain (Pidd) and apoptosis in oral squamous cell carcinoma
Bonnefoi et al. p53 as a potential predictive factor of response to chemotherapy: feasibility of p53 assessment using a functional test in yeast from trucut biopsies in breast cancer patients
Khokhar et al. Differential effects of p63 mutants on transactivation of p53 and/or p63 responsive genes
López-Terrada et al. Genetics and molecular biology of bone and soft tissue tumors
Nielsen‐Preiss et al. Detection and characterization of low abundance cellular proteins that specifically increase upon loss of the metastatic phenotype
AU2002251842A1 (en) Reagents and methods for identifying and modulating expression of genes regulated by CDK inhibitors
WO2001012858A1 (fr) APC A LIENS PPARδ POUR MEDICAMENTS DE CHIMIO-PREVENTION
Mizobuchi et al. Deteetkm of intratmnoral DNA heterogeneity in primary lung cancer using a multiple sampling method
Wright Function of DBCCR1, deleted in bladder cancer chromosome region 1
AU2006200921A1 (en) Reagents and methods for identifying and modulating expression of genes regulated by CDK inhibitors
EP1203101A1 (fr) Ppar delta relie apc aux medicaments de chimio-prevention

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004519674

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2491143

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/000159

Country of ref document: MX

Ref document number: 1020057000103

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003245743

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003739349

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057000103

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007128596

Country of ref document: US

Ref document number: 10520142

Country of ref document: US

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003739349

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10520142

Country of ref document: US